Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine aims to train immune system to fight neuroendocrine tumors

NCT ID NCT03879694

Completed Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a vaccine called SurVaxM in 19 people with metastatic neuroendocrine tumors. The vaccine is designed to teach the immune system to recognize and attack tumor cells that produce a protein called survivin. The main goal was to see if the vaccine is safe and whether it triggers an immune response, not yet to prove it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SurVaxM (survivin long peptide vaccine) combined with octreotide acetate and sargramostim
What this could lead to
If it works, this could point toward a new way to help the immune system attack neuroendocrine tumors that have spread.
What could go wrong
This is a very early, small phase 1 trial with only 19 people, so it is mainly checking safety, not whether the vaccine actually shrinks tumors. The vaccine may not produce a strong enough immune response to help patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG ATYPICAL CARCINOID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell atypical carcinoid tumor lung carcinoid tumor neuroendocrine neoplasm pancreatic neuroendocrine tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG ATYPICAL CARCINOID TUMOR LUNG TYPICAL CARCINOID TUMOR METASTATIC PANCREATIC NEUROENDOCRINE TUMOR

Contacts and locations

Locations

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.